Physicians' Academy for Cardiovascular Education
Click here to watch this as part of CME accredited course

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Click here to watch this as part of CME accredited course

Video navigation menu

  • Diabetes is an important comorbidity in HF. 00:19
  • The results of the EMPA-REG OUTCOME trial suggest that empagliflozin may prevent the development of HF 01:44
  • Considering that HF was not an inclusion criterium in EMPA-REG OUTCOME trial, what can we say about the type of HF that some developed?  05:21
  • What do the ESC guidelines say about management of HF with diabetes? 07:21
  • Outstanding questions on the use of SGLT2 inhibitors for treatment of HF 08:04

Educational information

The educational objectives of this symposium were to:

Faculty

Stefan D. Anker, MD is Professor of (Tissue)Homeostasis in Cardiology & Metabolism, Charité, Berlin, Germany

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

This symposium was supported by an unrestricted educational grant provided by Boehringer-Ingelheim/Lilly

View Biography and Keyslides

Share this page with your colleagues and friends: